A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs BMS 986165 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Jan 2018 Planned End Date changed from 29 Apr 2020 to 16 Sep 2020.
- 10 Jan 2018 Planned primary completion date changed from 8 Apr 2020 to 16 Sep 2020.
- 10 Jan 2018 Status changed from recruiting to active, no longer recruiting.